AR and prostate carcinoma: 57 depleted both canonical (EZH2:PRC2) and non-canonical (EZH2TAD:AR/AR-V7:co-activators) EZH2 complexes in prostate cancer cells, evoking significantly more robust antitumor effects than EZH2 catalytic inhibitors.84